immunoglobulin; monoclonal antibody; against the human multi-drug resistance antigen, P-glycoprotein
Permits/Forms:
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:
Animals were immunized with BALB/c 3T3 fibroblast cells, which were transfected with the human MDR1 gene and then selected for the drug resistance phenotype by growth in vinblastine-containing culture medium. [56193] Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. The murine hybridoma 15D3 recognizes the human multi-drug resistance antigen, P-glycoprotein. The antibody immunoprecipitates a 170- to 180-kDa protein from multi-drug resistance (MDR) cells, but does not block binding of the known anti-P-glycoprotein antibody MRK16. [56200] The antibody may be useful for diagnostic detection of MDR in patients undergoing chemotherapy or as targeting components of immunotherapeutic agents. [56200] The hybrid hybridoma cell lines 1B7 (ATCC HB-10500) and 1A7 (ATCC HB-10501) were formed by the fusion of the 15D3 (ATCC HB-11342) and 3G8 hybridoma cell lines. [56195]
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C
Subculturing:
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation:
culture medium 95%; DMSO, 5%
Related Products:
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005 recommended serum:ATCC 30-2020 derivative:ATCC HB-10500 derivative:ATCC HB-10501
References:
56193: Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000 56195: Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999 56196: Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000 56197: Ring DB. Nucleic acids encoding antigen-binding sites specific for cancer antigens. US Patent 5,948,647 dated Sep 7 1999 56199: Ring DB. Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer. US Patent 5,811,267 dated Sep 22 1998 56200: Shi T, et al. High-affinity monoclonal antibodies against P-glycoprotein. Clin. Immunol. Immunopathol. 76: 44-51, 1995. PubMed: 7541735